Clin2
NCT07092618Possibly a fitRecruiting

Trial for keeping weight off after stopping GLP-1 meds

LongevityGLP-1GeroscienceAging

Treatments studied

Part of Hormones & metabolism clinical trials.

This study tests if other medicines (naltrexone, metformin, or rapamycin) can help people keep off weight they lost while taking GLP-1 drugs like Wegovy or Ozempic, after they stop taking them. It is for AgelessRx patients aged 40 to 85 who have lost at least 15 pounds on GLP-1s.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
150 people
Ages
40 years to 85 years
Study type
Interventional

Who can take part

  • You are an existing patient of AgelessRx.
  • You are between 40 and 85 years old.
  • Your BMI is 22 or higher.
  • You have been taking GLP-1 drugs (Wegovy, Ozempic, or compounded forms) for at least three months.
  • You have lost at least 15 pounds while using GLP-1 drugs.
  • You do not have a history of weight-loss surgery or have not used other weight-loss drugs in the past six months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07535892Not yet recruiting
Behavioral Program for Weight Loss After Stopping GLP-1 Medications

This study tests a 6-month behavioral program (including exercise, diet, and mindfulness) designed to help you keep weight off after stopping GLP-1 or similar weight-loss medications. It's for people who have already lost at least 15% of their body weight and stopped or are stopping these medications.

Birmingham, Alabama
NCT07444073Not yet recruiting
Weight loss study with a biological aging blood test

This study looks at how a medical weight loss program affects biological aging using a simple blood test. It is for adults who are overweight or have obesity and may help show if weight loss can slow aging.

Singapore
NCT07092605Enrolling by invitation· Early Phase 1
Microdosed semaglutide for longer, healthier life

This trial tests whether a very low ('micro') dose of semaglutide can improve health, quality of life, and how long you live well. It's for people who are interested in the drug's general health benefits but not specifically for weight loss.

Ann Arbor, Michigan
NCT07209046Not yet recruiting
Probiotic for weight after stopping GLP-1 medication

This trial tests whether a probiotic supplement called UltraFlora Triplebiotic can help prevent weight gain after stopping a GLP-1 medication. If you recently stopped a GLP-1 drug, this study may help you maintain your weight.

NCT07270497Recruiting
New weight-loss medicines and diet changes in people with excess weight

This study tests whether a newer class of weight-loss medicines (GLP-1 and GIP/GLP-1 analogues) can help people with excess body weight eat healthier and improve their metabolism and behavior. It may be a good option if you are an adult with overweight or obesity and haven't used these medicines recently.

Warsaw, Warszawa
NCT07701460Not yet recruiting
Long-term effects after stopping GLP-1 weight loss medication

This study follows people who recently stopped taking a GLP-1 medication (like Wegovy or Ozempic) to understand how weight, eating habits, and daily routines change over time. It aims to help patients and doctors know what to expect after stopping the drug.

Boston, Massachusetts

Hear when a new Longevity trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.